✨ Free AI Report
Upstream Bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Upstream Bio, Inc.
Company Research

Upstream Bio, Inc.: Business Overview, Financials & Competitive Analysis

Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases focusing on severe respiratory disorders, with its lead candidate verekitug in Phase 2 clinical development for se...

Analyst-debate audio for Upstream Bio, Inc.

AskCyborg analysts argue the bull and bear cases for Upstream Bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

First-in-class TSLP antagonist with validated clinical efficacy, strong analyst backing, and significant market opportunity in...

Read the full analyst-debate transcript →
Industry Pharmaceutical Biotechnology - Respiratory/Inflammatory Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Upstream Bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Upstream Bio, Inc. Overview

Pro stress-test →

Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases focusing on severe respiratory disorders, with its lead candidate verekitug in Phase 2 clinical development for severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase 1 trials for COPD. The company recently achieved a critical milestone with positive Phase 2 trial data in February 2026.

Strategic Profile

Pro stress-test →

Verekitug is the only known antagonist currently in development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine positioned upstream of multiple signaling cascades affecting various immune-mediated diseases. This novel mechanism of action addresses significant unmet needs in respiratory inflammation treatment with potential applications beyond the initial respiratory disease focus.

Competitive Landscape

Pro stress-test →

Upstream Bio competes in the severe respiratory inflammation space against established therapies and newer biologics from larger pharma. The company's differentiated TSLP antagonism mechanism provides competitive advantages versus current standard-of-care asthma treatments and other emerging respiratory therapeutics, though success depends on Phase 2/3 trial progression.

Industry Context

Upstream Bio, Inc. operates in Pharmaceutical Biotechnology - Respiratory/Inflammatory Diseases.

Key facts

Founded: 2021 · Headquarters: Waltham, Massachusetts · Market cap: $1.68B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Upstream Bio, Inc..

  • Recently announced positive Phase 2 VALIANT trial results for severe asthma treatment (February 11, 2026)
  • Analyst consensus is bullish with Piper Sandler maintaining Overweight rating and $75 price target; Mizuho Outperform with $51 target
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Positive Phase 2 VALIANT trial results for severe asthma with verekitug announced
  • February 2026Evercore ISI maintained Buy rating on the stock
  • +1 moreTrack every material event for Upstream Bio, Inc. as it happens. Explore monitoring →
Get alerted when Upstream Bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DupilumabIL-4R antagonist for moderate-to-severe asthma and atopic dermatitis→MepolizumabIL-5 antagonist for eosinophilic asthma→ReslizumabIL-4 antagonist for moderate-to-severe asthma→

Compare Upstream Bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Upstream Bio, Inc. operates in Pharmaceutical Biotechnology - Respiratory/Inflammatory Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Biotechnology - Respiratory/Inflammatory Diseases research →
NEW · MCP server

Ask your AI assistant about Upstream Bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Upstream Bio, Inc. and its top competitor on Cyborg Score”
“What did Upstream Bio, Inc. do this quarter?”
“Is Upstream Bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Upstream Bio, Inc. do?+
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases focusing on severe respiratory disorders, with its lead candidate verekitug in Phase 2 clinical development for se...
What is Upstream Bio, Inc.'s Cyborg Score?+
Upstream Bio, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Upstream Bio, Inc.'s main competitors?+
Named competitors include Dupilumab, Mepolizumab, Reslizumab. The full competitive landscape is in the AskCyborg report.
How can I get the full Upstream Bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Upstream Bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Upstream Bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.